Journal of Shanghai Jiao Tong University (Medical Science) ›› 2024, Vol. 44 ›› Issue (4): 435-443.doi: 10.3969/j.issn.1674-8115.2024.04.003
• Basic tumor research column • Previous Articles
WANG Mengting(), CHEN Yinan, XUANYUAN Xinyang, YUAN Haihua()
Received:
2023-10-30
Accepted:
2024-03-25
Online:
2024-04-28
Published:
2024-04-28
Contact:
YUAN Haihua
E-mail:0_0ncwcncbc@sjtu.edu.cn;72300611229@shsmu.edu.cn
CLC Number:
WANG Mengting, CHEN Yinan, XUANYUAN Xinyang, YUAN Haihua. Construction and experimental validation of mouse PDX model by malignant pleural effusion-derived tumor cells from lung cancer[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(4): 435-443.
Add to citation manager EndNote|Ris|BibTeX
URL: https://xuebao.shsmu.edu.cn/EN/10.3969/j.issn.1674-8115.2024.04.003
No. | Histologic subtype | Tumor marker | TNM stage | Mutation | |||
---|---|---|---|---|---|---|---|
CK-7 | TTF1 | Napsin A | p40 | ||||
LC001 | AD | / | / | / | / | TxN3M0 | / |
LC002 | AD | + | + | + | / | TxN3M1 | EGFR L858R |
LC003 | NSCLC | / | / | / | / | T4N1M1 | / |
LC004 | AD | + | - | + | / | TxN3M1 | EGFR Exon20ins |
LC005 | AD | / | / | / | / | rTNM | EGFR L858R |
LC006 | AD | / | / | / | / | T4N3M1c | ALK, ROS1 |
LC007 | AD | + | + | + | / | T1N0M0 | PD-L1, TP53 |
LC008 | AD | / | / | / | / | TxN1M2 | EGFR Exon19del |
LC009 | AD | + | + | + | / | TxN1M1c | EGFR Exon18 |
LC010 | NSCLC | / | + | / | + | TxN3M1 | No mutation |
LC011 | NSCLC | / | / | / | / | TxN3M1 | / |
LC012 | SCC | / | / | / | / | T3N0M1c | / |
LC013 | NSCLC | + | - | - | - | TxN3M1c | / |
Tab 1 Information of established MPE-PDX
No. | Histologic subtype | Tumor marker | TNM stage | Mutation | |||
---|---|---|---|---|---|---|---|
CK-7 | TTF1 | Napsin A | p40 | ||||
LC001 | AD | / | / | / | / | TxN3M0 | / |
LC002 | AD | + | + | + | / | TxN3M1 | EGFR L858R |
LC003 | NSCLC | / | / | / | / | T4N1M1 | / |
LC004 | AD | + | - | + | / | TxN3M1 | EGFR Exon20ins |
LC005 | AD | / | / | / | / | rTNM | EGFR L858R |
LC006 | AD | / | / | / | / | T4N3M1c | ALK, ROS1 |
LC007 | AD | + | + | + | / | T1N0M0 | PD-L1, TP53 |
LC008 | AD | / | / | / | / | TxN1M2 | EGFR Exon19del |
LC009 | AD | + | + | + | / | TxN1M1c | EGFR Exon18 |
LC010 | NSCLC | / | + | / | + | TxN3M1 | No mutation |
LC011 | NSCLC | / | / | / | / | TxN3M1 | / |
LC012 | SCC | / | / | / | / | T3N0M1c | / |
LC013 | NSCLC | + | - | - | - | TxN3M1c | / |
1 | SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33. |
2 | ZHENG R S, ZHANG S W, ZENG H M, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 2(1): 1-9. |
3 | XU P W, TANG K, MA J W, et al. Chemotherapeutic tumor microparticles elicit a neutrophil response targeting malignant pleural effusions[J]. Cancer Immunol Res, 2020, 8(9): 1193-1205. |
4 | PORCEL J M, GASOL A, BIELSA S, et al. Clinical features and survival of lung cancer patients with pleural effusions[J]. Respirology, 2015, 20(4): 654-659. |
5 | SHIBAKI R, MURAKAMI S, SHINNO Y, et al. Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer[J]. Thorac Cancer, 2019, 10(4): 815-822. |
6 | SATOH K, MORISAWA S, OKUYAMA M, et al. Severe pleural effusion associated with nilotinib for chronic myeloid leukaemia: cross-intolerance with tyrosine kinase inhibitors[J]. BMJ Case Rep, 2021, 14(9): e243671. |
7 | WANG T F, CHU S C, LEE J J, et al. Presence of pleural effusion is associated with a poor prognosis in patients with epidermal growth factor receptor-mutated lung cancer receiving tyrosine kinase inhibitors as first-line treatment[J]. Asia Pac J Clin Oncol, 2017, 13(4): 304-313. |
8 | JIN K T, TENG L S, SHEN Y P, et al. Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review[J]. Clin Transl Oncol, 2010, 12(7): 473-480. |
9 | ROSCILLI G, de VITIS C, FERRARA F F, et al. Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity[J]. J Transl Med, 2016, 14: 61. |
10 | SUN S Q, ZHU J Q, MA Y, et al. Accuracy, robustness and scalability of dimensionality reduction methods for single-cell RNA-seq analysis[J]. Genome Biol, 2019, 20(1): 269. |
11 | ASHBURNER M, BALL C A, BLAKE J A, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium[J]. Nat Genet, 2000, 25(1): 25-29. |
12 | WAKEFIELD C E, DOOLAN E L, FARDELL J E, et al. The avatar acceptability study: survivor, parent and community willingness to use patient-derived xenografts to personalize cancer care[J]. EBioMedicine, 2018, 37: 205-213. |
13 | HEINRICH M A, MOSTAFA A M R H, MORTON J P, et al. Translating complexity and heterogeneity of pancreatic tumor: 3D in vitro to in vivo models[J]. Adv Drug Deliv Rev, 2021, 174: 265-293. |
14 | MAKIMOTO G, OHASHI K, TOMIDA S, et al. Rapid acquisition of alectinib resistance in ALK-positive lung cancer with high tumor mutation burden[J]. J Thorac Oncol, 2019, 14(11): 2009-2018. |
15 | PARK B, JEONG B C, CHOI Y L, et al. Development and characterization of a bladder cancer xenograft model using patient-derived tumor tissue[J]. Cancer Sci, 2013, 104(5): 631-638. |
16 | STOCKHAMMER P, HO C S L, HEGEDUS L, et al. HDAC inhibition synergizes with ALK inhibitors to overcome resistance in a novel ALK mutated lung adenocarcinoma model[J]. Lung Cancer, 2020, 144: 20-29. |
17 | 杨晓乐. 肺癌胸水肿瘤细胞的体外培养、鉴定及其对常规化疗药物敏感性研究[D]. 郑州: 郑州大学, 2017. |
YANG X L. Establishment and identification of malignant pleural effusion-derived lung cancer primary cell culture and its chemosensitivity[D]. Zhengzhou: Zhengzhou University, 2017. | |
18 | RUAN H Y, WANG Z, SUN Z W, et al. Single-cell RNA sequencing reveals the characteristics of cerebrospinal fluid tumour environment in breast cancer and lung cancer leptomeningeal metastases[J]. Clin Transl Med, 2022, 12(6): e885. |
19 | KIM N, KIM H K, LEE K, et al. Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma[J]. Nat Commun, 2020, 11(1): 2285. |
20 | KAO T W, BAI G H, WANG T L, et al. Novel cancer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance[J]. J Exp Clin Cancer Res, 2023, 42(1): 171. |
21 | KANG H N, CHOI J W, SHIM H S, et al. Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation[J]. Lung Cancer, 2018, 124: 168-178. |
22 | CHEN X M, SHEN C, WEI Z, et al. Patient-derived non-small cell lung cancer xenograft mirrors complex tumor heterogeneity[J]. Cancer Biol Med, 2021, 18(1): 184-198. |
23 | CHEN Y, ZHANG R, WANG L, et al. Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice[J]. Cancer, 2019, 125(21): 3738-3748. |
24 | WANG D, PHAM N A, TONG J F, et al. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors[J]. Int J Cancer, 2017, 140(3): 662-673. |
25 | KITA K, FUKUDA K, TAKAHASHI H, et al. Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance[J]. Cancer Sci, 2019, 110(10): 3215-3224. |
26 | STEWART E L, MASCAUX C, PHAM N A, et al. Clinical utility of patient-derived xenografts to determine biomarkers of prognosis and map resistance pathways in EGFR-mutant lung adenocarcinoma[J]. J Clin Oncol, 2015, 33(22): 2472-2480. |
27 | FICHTNER I, ROLFF J, SOONG R, et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers[J]. Clin Cancer Res, 2008, 14(20): 6456-6468. |
28 | ZHANG X C, ZHANG J C, LI M, et al. Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies[J]. J Transl Med, 2013, 11: 168. |
29 | LIAO H, ZHOU S X, CHEN S, et al. Establishment and characterization of patient-derived xenograft model of non-small-cell lung cancer derived from malignant pleural effusions[J]. Cancer Manag Res, 2023, 15: 165-174. |
30 | XIN Y Q, LI S Y, JIANG Q K, et al. Establishment of a jaw fibrosarcoma patient-derived xenograft and evaluation of the tumor suppression efficacy of plumbagin against jaw fibrosarcoma[J]. Front Oncol, 2020, 10: 1479. |
31 | HUANG T L, CHEN B Y, WANG F, et al. Rab1A promotes IL-4R/JAK1/STAT6-dependent metastasis and determines JAK1 inhibitor sensitivity in non-small cell lung cancer[J]. Cancer Lett, 2021, 523: 182-194. |
[1] | HUANG Huayan, XU-ZHANG Wendi, XIA Liliang, YU Yongfeng, LU Shun. Advances in immunotherapy of advanced non-small cell lung cancer with EGFR mutation [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(5): 611-618. |
[2] | ZHAO Zhuoming, LIU Zhenhao, LU Manman, ZHANG Yu, XU Linfeng, XIE Lu. Analysis of tumor-related features of non-small cell lung cancer based on TCR repertoire workflow [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(12): 1520-1528. |
[3] | ZHAO Keke, JIANG Beibei, ZHANG Lu, WANG Lingyun, ZHANG Yaping, XIE Xueqian. Feasibility of ultra-low-dose noncontrast CT based on deep learning image reconstruction to evaluate chest lesions [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(8): 1062-1069. |
[4] | LIAO Yahui, LIU Liyun, ZHU Hongrui, LIN Houwen, YAN Jizhou, SUN Fan. Marine sponge-derived smenospongine overcomes resistance of cisplatin via inhibiting EGFR-Akt-ABCG2 pathway in NSCLC cells [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(8): 997-1007. |
[5] | LIU Ziyang, WANG Xiaowen, CHEN Li. lncRNA GK-IT1 influences the carcinogenesis of non-small cell lung cancer cells through regulating aldolase A [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(5): 591-601. |
[6] | LU Wenqing, MENG Zhouwenli, YU Yongfeng, LU Shun. Resistance mechanisms and overcoming strategies of the third-generation EGFR-TKI in non-small cell lung cancer [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(4): 535-544. |
[7] | HU Chanchan, FAN Yi, XU Yuan, HU Zhijian, ZENG Yiming. Lipid metabolism and lung cancer: emerging roles in occurrence, progression, diagnosis and treatment [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(12): 1766-1771. |
[8] | LIAO Hongjian, CAO Yuchao, DU Yonghong. Anticancer effect of drug-loaded DNA nanoflowers on mouse lung cancer cells [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(11): 1542-1549. |
[9] | LI Ruonan, CHEN Xiaoke, XU Yuanyuan, TAN Qiang. Advances in postoperative adjuvant targeted therapy for patients with stage ⅠB-ⅢA non-small cell lung cancer [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(11): 1612-1619. |
[10] | Yu ZHANG, Xiaoyuan WU, Lihua GUAN, Yiyuan LIU, Xingyue PENG, Haiyan XIE, Wei HU, Keke HAO, Ning XIA, Guojun LU, Zhibo HOU. Application of high-throughput drug sensitivity screening system in the treatment of non-small cell lung cancer with malignant pleural effusion [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2022, 42(1): 82-89. |
[11] | Bing-qian ZHOU, Li HAN, Zhe-yi CHEN, Shi-yu CHEN, Ying-xia ZHENG. Expression of protein arginine methyltransferase 5 in lung cancer and its mechanism of promoting lung cancer [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(8): 1009-1016. |
[12] | Xu-xin-yi LING, Yao ZHANG, Hua ZHONG. Research progress in screening non-small cell lung cancer patients who will benefit from immunotherapy [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(8): 1114-1119. |
[13] | Yan-qi HE, Rui CHI, Meng-ping CHEN, Si CHEN, Chun-liang LIU, Yun-xia LIU, Hai-peng SUN. Function of branched-chain amino acid catabolism in lung cancer cells [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(7): 858-864. |
[14] | Yun-fang MA, Li-na PAN, Zhen LI, Bei-li GAO, Jia-an HU, Zhi-hong XU. Exploratory study on downregulation of PD-L1 in KRAS G12V-mutant non-small cell lung cancer cells by selumetinib [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(6): 741-748. |
[15] | Jian-hua XU, Ping JIANG, Jiong DENG. Expression and significance of ATP-binding cassette superfamily G member 2 in lung cancer [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(6): 830-833. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||